Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.


TSX:MSCL - Post by User

Bullboard Posts
Post by extreme22on Jul 23, 2009 9:32am
325 Views
Post# 16159638

Financing closed and accepted by TSX

Financing closed and accepted by TSX$0$0iCo Therapeutics 1,187,500-share private placement$0$0$0$0$02009-07-22 19:23 ET - Private Placement$0$0The TSX Venture Exchange has accepted for filing documentation with respect to a non-brokered private placement announced July 16, 2009:$0$0$0$0Number of shares:  1,187,500 shares$0$0Purchase price:  40 cents per share$0$0Hidden placees:  17 hidden placees participated$0$0Pro groups:  Scott Hunter, 100,000; Christian ter Keurs, 200,000$0$0Insiders:  Andrew Rae, 30,000; John Clement, 6,250$0$0Finders' fees:  7 per cent in cash based on the proceeds raised by each payable to Haywood Securities ($2,800), Pathfinder Ventures Corp. (Greg Andrews) ($3,500), Pure Advertising & Marketing (Kam Thindal) ($8,400), Loewen, Ondaatje, McCutcheon ($3,500), and B&D Capital (Don Mosher) ($2,100)$0
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse